Updated : Feb 03, 2021 Relationships

Global Erythropoietin Drugs Market


Global erythropoietin drugs market was valued US$ 7.6 Bn in 2019 and is expected to reach US$ 17.8 Bn by 2026, at a CAGR of 11.22 % during a forecast period.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.

Erythropoietin drugs are also known as hematopoietin and that controls erythropoiesis as well as production of red blood cells. They are used in treatment of various diseases like cancer, chronic renal diseases, AIDS, anaemia and etc.

Erythropoietin market is driven by growing prevalence of chronic diseases like cancer, AIDA and renal diseases. Introduction of new drugs and different government initiatives for research are also boosting the growth of erythropoietin drugs market. However, the high cost of treatment, as well as side effects of the treatment, are limiting the growth of market.
Biosimilar is the fastest growing segment in the erythropoietin drugs market, especially in developing countries, owing to low-cost therapeutics and enhanced efficacy. Biosimilar is easy to change & improve, cost-effective, and require less time for approval as compared to biologics and are expected to gain popularity in the near future for the treatment of anemic conditions.

In cancer patients, almost 77% suffer from anemia, which is often overlooked as tiredness. Anemia is generally associated with cancer, owing to chemotherapy treatment, blood loss, marrow tumor, nutritional deficiency, but is mostly caused due to cytokine production.

Retail pharmacies in distribution channel segment leading the global erythropoietin drugs market with a huge share. Retail pharmacist providing advice about health issues, symptoms & medications in response to customer inquiries, recruiting, training & managing staff, treating prescriptions & dispensing medication. Retail pharmacies are also preparing publicity materials & displays, managing budgets, and keeping statistical & financial records.

North America is leading the largest market, followed by Europe during the forecast period owing to constantly growing cancer populace and the patient suffering from renal diseases in North America. Technological advance and governmental initiatives for research are also leading the largest market in this region. Growing purchasing power, rapid growth in infrastructure, rising medical tourism and expansion in available treatments is increasing the growth of the Asia Pacific region in the erythropoietin drugs market during the forecast period.

Key player operating in the global erythropoietin drugs market are Amgen, Hoffmann-LA Roche, Johnson & Johnson, and Kyowa Hakko Kirin.
The report covers a comprehensive study of major market drivers, restrains, opportunities, challenges, PESTEL, Porters, SWOT, and technological forecasting in the market.

For More Information Visit:

https://www.maximizemarketresearch.com/market-report/global-erythropoietin-drugs-market/23866/


The Scope of Global Erythropoietin Drugs Market:

Global Erythropoietin Drugs Market, by Drug Class:

• Epoetin Alfa
• Epoetin Beta
• Darbepoetin Alfa
Global Erythropoietin Drugs Market, by Drug Type:

• Biologics
• Biosimilar
Global Erythropoietin Drugs Market, by Drug Application:

• Cancer
• Renal Disease
• Hematology
• Neurology
• Surgery & Wound Healing
Global Erythropoietin Drugs Market, by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Global Erythropoietin Drugs Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa
Key Player Operating In the Global Erythropoietin Drugs Market:

• Amgen
• Hoffmann-LA Roche
• Johnson & Johnson
• Kyowa Hakko Kirin
• Ahua Pharmaceutical
• 3SBio
• BIOSIDUS
• Biocon
• Boehringer Ingelheim
• Chugai Pharmaceutical
• Celltrion
• Intas Pharmaceuticals
• Cipla
• DAICHI SANKYO
• Dr. Reddy’s Laboratories
• Teva Pharmaceutical Industries
• Dragon Pharma
• Huaxin High Biotechnology
• JCR Pharmaceuticals
• Shanghai Kehua Bio-Engineering
• LG Life Science
• Novartis
• Pfizer
• Sandoz International
• Shenyang Sunshine Pharmaceutical
• Shenzhen Sai Bao Er Bio-Pharmaceutical
• Sihuan Pharmaceutical
• STADA
• Uni-Bio Science
• Wanbang Biochemical Pharmaceuticals

This Report Is Submitted By :Maximize Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: LumawantGodage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address : Pune, Maharashtra 411051, India.

Contact: +919607195908

SHARE NOW

Leave a Reply

Your email address will not be published. Required fields are marked *